Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Peripheral artery disease (PAD) is a major complication of atherosclerosis when blockages in
the arteries to leg reduce blood flow and one of the resulting problems is termed
intermittent claudication (IC). IC is leg pain with walking that is relieved with rest and IC
is the most frequent clinical manifestation of PAD and it effects millions of Americans. The
number of patients with, and the health care costs of, PAD will increase as the prevalence of
PAD is associated with advancing age, diabetes, and smoking. Zibotentan (ZD4054) is an
endothelin receptor A (ETA) blocker that undergone extensive human testing and has been shown
to be safe in several patient population. There is ample evidence to suggest that an ETA
blocker could improve blood flow to the legs in patients with PAD. In a study that will be
funded by the National Institute of Health, the investigators will test the ability of this
medication to allow better blood flow to the legs of patients with PAD. In patients with IC,
the investigators will test the ability of ZD4054 to improve leg blood flow using a
non-invasive imaging technique. In parallel the study will test for the ability of patients
with leg pain to walk further and feel better.